Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Real-World Data Show Enfortumab Vedotin Significantly Improves OS in Urothelial Carcinoma
February 14th 2025, 8:27pm
Genitourinary Cancers Symposium (ASCO GU)
Enfortumab vedotin significantly improved outcomes for patients with unresectable or metastatic urothelial carcinoma, according to real-world data.
Axatilimab, Ruxolitinib, and Belumosudil Combo Elicits Responses in Chronic GVHD
February 14th 2025, 7:47pm
Transplantation and Cellular Therapy Meetings
Favorable responses were demonstrated with the treatment of axatilimab plus ruxolitinib/belumosudil in heavily pretreated patients with chronic GVHD.
Transdermal Estradiol Plus ARPIs Demonstrate Comparable PSA Response to LHRHa in Metastatic Prostate Cancer
February 14th 2025, 6:15pm
Genitourinary Cancers Symposium (ASCO GU)
Responses were similar among patients with estrogen patches and ARPIs compared to aLHRH and ARPIs in metastatic prostate cancer.
Dr Shah on Efficacy Data for Zamto-Cel in R/R DLBCL
February 14th 2025, 6:01pm
Transplantation and Cellular Therapy Meetings
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma
Dr Dholaria on the Safety and Efficacy of P-BCMA-ALLO1 in R/R Myeloma
February 14th 2025, 5:58pm
Transplantation and Cellular Therapy Meetings
Dr Dholaria discusses the phase 1 trial of P-BCMA-ALLO1, highlighting high response rates, rapid CAR T-cell expansion, and a favorable safety profile in RRMM.
Dr Ahmed on NKTR-255 With CD19-Directed CAR T-Cell Therapy in R/R LBCL
February 14th 2025, 5:24pm
Transplantation and Cellular Therapy Meetings
Sairah Ahmed, MD, discusses evaluating NKTR-255 in combination with CD19-directed CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma.
P-BCMA-ALLO1 Is Safe and Efficacious in R/R Multiple Myeloma
February 14th 2025, 5:22pm
Transplantation and Cellular Therapy Meetings
P-BCMA-ALLO1 displayed early efficacy and safety data in relapsed/refractory multiple myeloma.
Zamto-Cel Delivers Responses in R/R Diffuse Large B-Cell Lymphoma
February 14th 2025, 4:22pm
Transplantation and Cellular Therapy Meetings
Zamto-cel produced responses and was associated with low rates of CD19 and/or CD20 antigen loss in relapsed/refractory diffuse large B-cell lymphoma.
Olaparib Plus Abiraterone Improves Radiographic PFS and OS in BRCA+ mCRPC
February 14th 2025, 2:00am
Genitourinary Cancers Symposium (ASCO GU)
First-line therapy with olaparib plus abiraterone demonstrated clinical benefit in rPFS and OS in mCRPC harboring germline and somatic BRCA mutations.
Dr Goy on Unclear Survival Benefit With Neoadjuvant ADT Plus EBRT in Intermediate-Risk Prostate Cancer
February 14th 2025, 1:13am
Genitourinary Cancers Symposium (ASCO GU)
Barry W. Goy, MD, discusses 15-year survival outcomes with neoadjuvant androgen deprivation therapy plus EBRT in intermediate-risk prostate cancer.
Dr Saad on the Efficacy of Darolutamide Plus ADT In Low and High Volume mHSPC
February 14th 2025, 12:34am
Genitourinary Cancers Symposium (ASCO GU)
Fred Saad, CQ, MD, FRCS, FCAHS, discusses the efficacy and safety of darolutamide plus ADT in mHSPC according to disease volume.
Darolutamide Plus ADT Is Efficacious in mHSPC Regardless of Disease Volume
February 13th 2025, 10:49pm
Genitourinary Cancers Symposium (ASCO GU)
The addition of darolutamide to ADT improved rPFS and other efficacy end points vs placebo plus ADT in mHSPC.
EBRT With or Without STAD Shows Improved 15-Year Survival in Prostate Cancer
February 13th 2025, 10:22pm
Genitourinary Cancers Symposium (ASCO GU)
Treatment of EBRT with or without STAD for 6 months demonstrated an improvement in prostate cancer-specific survival in intermediate-risk prostate cancer.
Composite Gene Expression Score Shows Potential to Predict Bavdegalutamide Benefit in mCRPC
February 13th 2025, 10:15pm
Genitourinary Cancers Symposium (ASCO GU)
A low composite gene expression score was associated with improved outcomes in patients with mCRPC who received bavdegalutamide.
G-CSF Allows for Efficacious Dose of Docetaxel With ARASENS Regimen in mHSPC
February 13th 2025, 9:46pm
Genitourinary Cancers Symposium (ASCO GU)
G-CSF use and docetaxel dose modifications allowed patients with mHSPC to receive efficacious doses of docetaxel in the ARASENS trial.
Lutetium Lu 177 Vipivotide Tetraxetan Plus Enzalutamide Boosts OS in mCRPC
February 13th 2025, 9:42pm
Genitourinary Cancers Symposium (ASCO GU)
Adding Lu-PSMA-617 to enzalutamide significantly improved overall survival and quality of life in metastatic castration-resistant prostate cancer.
Anakinra Fails to Reduce CRS, ICANS Associated With Liso-Cel in LBCL
February 13th 2025, 6:58pm
Transplantation and Cellular Therapy Meetings
Anakinra did not reduce cytokine release syndrome or immune effector cell–associated neurotoxicity in patients with large B-cell lymphoma receiving liso-cel.
Dr Ahluwalia on the Evolution of Precision Medicine in Oncology
February 13th 2025, 6:45pm
Miami Cancer Institute Precision Oncology Symposium
Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses oncology advances that were highlighted at the Miami Cancer Institute Precision Oncology Symposium.
Dr McCann on the Treatment Paradigm for HER2+ Breast Cancer With Brain Metastases
February 13th 2025, 6:40pm
Miami Cancer Institute Precision Oncology Symposium
Kelly E. McCann, MD, PhD, discusses current and evolving treatment strategies for patients with HER2-positive breast cancer who develop brain metastases.
NKTR-255 Plus Anti-CD19 CAR T-Cell Therapy Demonstrates Safety and Preliminary Efficacy in R/R LBCL
February 13th 2025, 5:41pm
Transplantation and Cellular Therapy Meetings
NKTR-255 combined with CD19-directed CAR T-cell therapy improved 6-month CR rates vs placebo in patients with relapsed/refractory large B-cell lymphoma.